



Intended for UK Media

HIPRA's protein-based COVID-19 vaccine available in the UK for the 2026/27 autumn vaccination programme

A choice of vaccine for the 2026 autumn COVID-19 vaccination programme will be made available through a partnership with Accord Healthcare

West London / Girona, September 8, 2026 – HIPRA, a European biopharmaceutical company announces that its protein-based COVID-19 vaccine, BIMERVAX® ▼LP.8.1¹ (COVID-19 Vaccine (recombinant, adjuvanted)), will be available in the **United Kingdom as part of the UK's 2026/27 autumn COVID-19 vaccination programme**. The provision of the vaccine in the UK has been enabled through a strategic partnership with **Accord Healthcare, a leading pharmaceutical company headquartered in London**.

“We are delighted to collaborate with HIPRA to bring BIMERVAX® to the UK. This partnership reflects our joint commitment to improving access by expanding the range of vaccination options available to health authorities, healthcare professionals and eligible individuals.”, said **Paul Tredwell, Chief Executive Officer, Accord Healthcare**.

A European-developed and manufactured vaccine

HIPRA's COVID-19 vaccine is researched, developed, manufactured and finished **entirely in Europe**, with every stage of the process taking place on the continent.

The COVID-19 vaccine is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. Different vaccine platforms potentially bring different advantages, whether in terms of tolerability, durability of protection, or operational characteristics (handleability). Maintaining a range of vaccine technologies within immunisation programmes is important to support programme flexibility² and choice for healthcare systems and eligible individuals.

Guidance from the **Joint Committee on Vaccination and Immunisation (JCVI)** includes a statement on the importance of having protein-based vaccines available as alternatives to mRNA vaccines, when selecting the most appropriate vaccination for eligible individuals.

“Making HIPRA's protein-based COVID-19 vaccine available in the UK strengthens the vaccination programme by offering choice to programme designers, and healthcare professionals. A diversified vaccine portfolio



enables a more nuanced approach to protecting vulnerable populations by potentially optimising overall programme design, while strengthening resilience and flexibility as COVID-19 becomes a routinely encountered respiratory infection," said **Emeritus Professor Sir Jonathan Van-Tam, public health expert and former Deputy Chief Medical Officer of England.**

The agreement marks an important milestone in **HIPRA's international growth strategy** and further strengthens the company's presence in one of Europe's leading healthcare markets.

As a European biopharmaceutical company, HIPRA remains committed to developing vaccine solutions and contributing to public health **by supporting vaccination programmes and improving access to immunisation.**

About HIPRA

HIPRA is a biotechnological pharmaceutical company focused on prevention in animal and human health (One Health), with a wide range of vaccines and an advanced diagnostic service. With its claim **"Building immunity for a healthier world"**, HIPRA reaffirms its commitment to contributing solutions that improve global health.

The company has a strong international presence with **40 subsidiaries, 3 R&D centers and 6 production facilities** strategically located in Europe (Spain) and the Americas (Brazil). In addition, its extensive international distribution network keeps commercial channels open in nearly 100 additional countries, thus covering all five continents.

Research and development are at the core of its expertise. HIPRA invests **around the 15% of its annual revenue to R&D activities and infrastructure**, focused on the creation and application of the latest scientific advances for the development of innovative vaccines of the highest quality. HIPRA has a portfolio of vaccines based on different technological platforms, with R&D teams working with a broad range of technologies and biological modalities.

To add further value to its expertise in vaccination, the company also develops medical devices and traceability services for animal health.

About Accord Healthcare

Headquartered in the United Kingdom, Accord Healthcare is one of the fastest growing pharmaceutical companies in Europe and provides large-scale generic pharmaceuticals, biosimilars and branded medicines in 85 countries globally. Accord delivers affordable medicines to national health systems supporting healthcare professionals to transform patient lives worldwide. Accord is driven to think differently and deliver more for the benefit of patients, always seeking to improve products and patients' access to them.

Accord has a strong heritage and expertise in oncology, with over 50 oncology-related treatments across its portfolio and a strong pipeline of future biosimilars and specialty medicines. As one of the largest suppliers of chemotherapy products in Europe, one in three oncology injectables are Accord products. In addition to its core business in off-patent and specialty



medicines, Accord has a diversified growth model, with business units advancing treatments in plasma-derived medicines, vaccines and animal health.

HIPRA media contacts

Irene Calle – icalle@harmon.es – M. +34 609 873 052

José María Nieto – jnieto@harmon.es – M. +34 689 186 062

Sara Mancebo – smancebo@harmon.es – M. +34 628 388 791

Accord Healthcare media contacts

Ian Weatherhead – ian_weatherhead@accord-healthcare.com – M. +44 7435 216669

Nick Johnson – nick_johnson@accord-healthcare.com – M. +44 7435 220822

References

1. BIMERVAX® Summary of Product Characteristics (SmPC). Available from: <https://mhraproducts4853.blob.core.windows.net/docs/82bdc378f23cea5bbe929129ecc7572e258e43f5>
2. COVID Transition Initiative. COVID Transition Roadmap [Internet]. 2024 May [cited 2026 Aug 24]. Available from: <https://www.covid-transition.com/files/roadmap-en.pdf>

▼ This medicinal product is subject to additional monitoring, as indicated by the presence of the inverted black triangle. Any suspected adverse reactions should be reported through the Yellow Card Scheme.